| Molecular cloning and expression of a rat Via arginine vasopressin receptor A Morel, AM O'Carroll, MJ Brownstein, SJ Lolaft Nature 356 (6369), 523-526, 1992 | 614 | 1992 |
| Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus SJ Lolait, AM O'Carroll, OW McBride, M Konig, A Morel, MJ Brownstein Nature 357 (6376), 336-339, 1992 | 609 | 1992 |
| Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and … L Gamelin, M Boisdron-Celle, R Delva, V Guérin-Meyer, N Ifrah, A Morel, ... Clinical Cancer Research 10 (12), 4055-4061, 2004 | 503 | 2004 |
| Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with … E Gamelin, R Delva, J Jacob, Y Merrouche, JL Raoul, D Pezet, E Dorval, ... Journal of clinical oncology 26 (13), 2099-2105, 2008 | 413 | 2008 |
| Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients E Rouits, M Boisdron-Celle, A Dumont, O Guérin, A Morel, E Gamelin Clinical Cancer Research 10 (15), 5151-5159, 2004 | 366 | 2004 |
| Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance A Morel, M Boisdron-Celle, L Fey, P Soulie, MC Craipeau, S Traore, ... Molecular cancer therapeutics 5 (11), 2895-2904, 2006 | 301 | 2006 |
| 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency M Boisdron-Celle, G Remaud, S Traore, AL Poirier, L Gamelin, A Morel, ... Cancer letters 249 (2), 271-282, 2007 | 268 | 2007 |
| Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis D Rosmarin, C Palles, D Church, E Domingo, A Jones, E Johnstone, ... Journal of Clinical Oncology 32 (10), 1031, 2014 | 260 | 2014 |
| Neuropoietin, a new IL-6-related cytokine signaling through the ciliary neurotrophic factor receptor D Derouet, F Rousseau, F Alfonsi, J Froger, J Hermann, F Barbier, ... Proceedings of the National Academy of Sciences 101 (14), 4827-4832, 2004 | 213 | 2004 |
| Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway L Gamelin, O Capitain, A Morel, A Dumont, S Traore, LB Anne, S Gilles, ... Clinical Cancer Research 13 (21), 6359-6368, 2007 | 160 | 2007 |
| GPL, a novel cytokine receptor related to GP130 and leukemia inhibitory factor receptor C Diveu, E Lelievre, D Perret, AHL Lak-Hal, J Froger, C Guillet, ... Journal of Biological Chemistry 278 (50), 49850-49859, 2003 | 147 | 2003 |
| A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker D Besson, AH Pavageau, I Valo, A Bourreau, A Bélanger, ... Molecular & Cellular Proteomics 10 (12), 2011 | 137 | 2011 |
| Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy L Gamelin, M Boisdron-Celle, A Morel, AL Poirier, V Berger, E Gamelin, ... Journal of Clinical Oncology 26 (7), 1188-1189, 2008 | 136 | 2008 |
| The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer O Capitain, M Boisdron-Celle, AL Poirier, S Abadie-Lacourtoisie, A Morel, ... The pharmacogenomics journal 8 (4), 256-267, 2008 | 123 | 2008 |
| Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients N Azzopardi, T Lecomte, D Ternant, M Boisdron-Celle, F Piller, A Morel, ... Clinical Cancer Research 17 (19), 6329-6337, 2011 | 116 | 2011 |
| The Phenolic compound Kaempferol overcomes 5-fluorouracil resistance in human resistant LS174 colon cancer cells I Riahi-Chebbi, S Souid, H Othman, M Haoues, H Karoui, A Morel, ... Scientific reports 9 (1), 195, 2019 | 113 | 2019 |
| Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study O Capitain, A Asevoaia, M Boisdron-Celle, AL Poirier, A Morel, E Gamelin Clinical colorectal cancer 11 (4), 263-267, 2012 | 112 | 2012 |
| The modulatory effects of the anxiolytic etifoxine on GABAA receptors are mediated by the β subunit A Hamon, A Morel, B Hue, M Verleye, JM Gillardin Neuropharmacology 45 (3), 293-303, 2003 | 106 | 2003 |
| Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis N Clere, I Corre, S Faure, AL Guihot, E Vessieres, M Chalopin, A Morel, ... International journal of cancer 127 (10), 2279-2291, 2010 | 96 | 2010 |
| Enzymes that process somatostatin precursors. A novel endoprotease that cleaves before the arginine-lysine doublet is involved in somatostatin-28 convertase activity of rat … P Gluschankof, S Gomez, A Morel, P Cohen Journal of Biological Chemistry 262 (20), 9615-9620, 1987 | 93 | 1987 |
jean-luc RaoulVerified email at ico.unicancer.fr
